| Non-viral precision T cell receptor replacement for personalized cell therapy SP Foy, K Jacoby, DA Bota, T Hunter, Z Pan, E Stawiski, Y Ma, W Lu, ... Nature 615 (7953), 687-696, 2023 | 187 | 2023 |
| Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy C Puig-Saus, B Sennino, S Peng, CL Wang, Z Pan, B Yuen, B Purandare, ... Nature 615 (7953), 697-704, 2023 | 100 | 2023 |
| Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines SS Raikar, LC Fleischer, R Moot, A Fedanov, NY Paik, KA Knight, ... Oncoimmunology 7 (3), e1407898, 2018 | 84 | 2018 |
| Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC CD Porada, C Sanada, CJ Kuo, E Colletti, W Mandeville, J Hasenau, ... Experimental hematology 39 (12), 1124-1135. e4, 2011 | 69 | 2011 |
| Functional aspects of factor VIII expression after transplantation of genetically‐modified hematopoietic stem cells for hemophilia A LM Ide, NN Iwakoshi, B Gangadharan, S Jobe, R Moot, D McCarty, ... The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2010 | 47 | 2010 |
| Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors R Moot, SS Raikar, L Fleischer, M Querrey, DE Tylawsky, H Nakahara, ... Molecular Therapy-Oncolytics 3, 2016 | 40 | 2016 |
| High-throughput screening identifies compounds that enhance lentiviral transduction JM Johnston, G Denning, R Moot, D Whitehead, J Shields, JM Le Doux, ... Gene Therapy 21 (12), 1008-1020, 2014 | 22 | 2014 |
| Simplified prototyping of perfusable polystyrene microfluidics R Tran, B Ahn, D R Myers, Y Qiu, Y Sakurai, R Moot, E Mihevc, ... Biomicrofluidics 8 (4), 2014 | 14 | 2014 |
| Engineering CD5-targeted chimeric antigen receptors and edited T cells for the treatment of T-cell leukemia LC Fleischer, SS Raikar, R Moot, KA Knight, CB Doering, HT Spencer Blood 130, 1914, 2017 | 12 | 2017 |
| Improving lentiviral transduction efficiency with microfluidic systems R Tran, DR Myers, JE Shields, B Ahn, Y Qiu, C Hansen, Y Sakurai, ... Blood, The Journal of the American Society of Hematology 126 (23), 4415-4415, 2015 | 7 | 2015 |
| Phenotypic correction of hemophilia A by postnatal intraperitoneal transplantation of FVIII-expressing MSC C Porada, C Sanada, E Kuo, E Colletti, R Moot, C Doering, HT Spencer, ... Blood 116 (21), 249, 2010 | 5 | 2010 |
| Abstract NG11: Landscape analysis of neoepitope-specific T-cell responses to immunotherapy C Puig-Saus, B Sennino, B Purandare, D An, B Quach, S Peng, H Xia, ... Cancer Research 80 (16_Supplement), NG11-NG11, 2020 | 3 | 2020 |
| NeoTCR-P1, a novel neoepitope-specific adoptive cell therapy, consists of T cells with ‘younger’phenotypes that rapidly proliferate and kill target cells upon recognition of … B Sennino, A Conroy, B Purandare, A Litterman, K Jacoby, R Moot, W Lu, ... Cancer Research 79 (13_Supplement), 1433-1433, 2019 | 3 | 2019 |
| 1478 A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T … S Foy, K Jacoby, D Bota, T Hunter, A Schoenfeld, Z Pan, E Stawiski, Y Ma, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 2 | 2022 |
| Highly efficient, non-viral precision genome engineering for the generation of personalized neoepitope-specific adoptive T cell therapies K Jacoby, R Moot, W Lu, D Nguyen, B Sennino, A Conroy, B Purandare, ... Cancer Research 79 (13_Supplement), 4783-4783, 2019 | 2 | 2019 |
| Expanding the ligand binding repertoire of chimeric antigen receptors using lamprey variable lymphocyte receptors R Moot, S Raikar, LC Fleischer, D McCarty, M Querrey, CB Doering, ... Blood 126 (23), 3244, 2015 | 2 | 2015 |
| Non-viral homology mediated end joining A Cooper, PK Hsu, R Moot, A Truong, T Gardner, B Hsu US Patent App. 18/379,912, 2024 | | 2024 |
| 123 Landscape analysis of the neoepitope-specific T cell responses in patients with and without clinical benefit from immune checkpoint blockade therapy CP Saus, B Sennino, S Peng, Z Pan, B Yuen, B Purandare, K Jacoby, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| An ultra-sensitive and high-throughput technology (imPACT) for the identification and isolation of intrinsic and emergent neoepitope-specific T cells from the peripheral blood … S Peng, B Quach, D An, S Sandoval, R Bao, Z Pan, M Bethune, O Dalmas, ... Cancer Research 79 (13_Supplement), 1435-1435, 2019 | | 2019 |
| Novel immunogen-specific variable lymphocyte receptors for creation of chimeric antigen receptors and methods for improved transduction and gene delivery R Moot | | 2018 |
